Clinical Trials Logo

Multiple Organ Failure clinical trials

View clinical trials related to Multiple Organ Failure.

Filter by:

NCT ID: NCT01315782 Recruiting - Sepsis Clinical Trials

Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis

Start date: December 2016
Phase:
Study type: Observational

This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ failure. The measurement of alveolar dead space used to require sophisticated equipment and time. New ventilators have microprocessors that allow rapid mathematical calculation with minimal intervention.

NCT ID: NCT01275976 Terminated - Sepsis Clinical Trials

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture

CAESAR
Start date: April 2012
Phase: Phase 3
Study type: Interventional

Trauma and major operation are associated with an excessive inflammation reaction due to tissue injury. This overwhelming immune response is considered to be a major risk factor in the pathogenesis of late inflammatory complications such as acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS) and sepsis. The investigators hypothesize that administration of C1-esterase inhibitor (C1-INH) will attenuate the humane inflammatory response and, thereby, reduce the risk of inflammatory complications due to surgical interventions in trauma patients with a femur or pelvic fracture

NCT ID: NCT01186783 Recruiting - Clinical trials for Multiple Organ Dysfunction Syndrome

Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine

MODIfY
Start date: May 2010
Phase: Phase 2
Study type: Interventional

MODIfY is a prospective, single center, open label, randomized, controlled two arms, Phase II-trial to evaluate the ability of ivabradine to reduce an elevated heart rate in Multiple Organ Dysfunction Syndrome (MODS) patients. The primary end point is the proportion of patients with a reduction of heart rate by at least 10 beats per minute (bpm) within 4 days. This trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed MODS (Acute Physiology and Chronic Health Evaluation (APACHE) II-score ≥ 20, diagnosis within ≤ 24 hours), with an elevated heart rate (sinus rhythm with HR ≥ 90 bpm) and contraindications to beta-blockers (BBs). Treatment period will last 4 days. All patients will be followed for up to six months.

NCT ID: NCT00965328 Completed - Acute Renal Failure Clinical Trials

Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration

Start date: February 2007
Phase: Phase 4
Study type: Interventional

The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding. Aim of the present study is to determine 1. whether nadroparin accumulates in plasma 2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose 3. the effects of nadroparin during critical illness on coagulation and anticoagulation

NCT ID: NCT00908635 Recruiting - Sepsis Clinical Trials

The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)

Start date: July 2008
Phase: N/A
Study type: Observational

This study is designated to determine serum concentrations of inflammatory mediators Ang-1, Ang-2, Ang-1/Ang-2 ratio, and Tie-2 in patients with sepsis-induced MODS and to investigate the association among increased permeability, inflammatory mediators, and these serum mediators in development of organ failure.

NCT ID: NCT00752245 Withdrawn - Renal Failure Clinical Trials

Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis

Start date: July 31, 2008
Phase: N/A
Study type: Interventional

Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with sepsis/multi-organ failure. The sampling of blood and dialysate will be done during dialyses with different durations (4, 6 and 8h)

NCT ID: NCT00736827 Completed - Sepsis Clinical Trials

BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients

BICUK
Start date: August 2008
Phase: N/A
Study type: Observational

The purpose of this study is to find out whether acute renal failure is associated with BK virus reactivation in postoperative/posttraumatic critically ill patients with severe SIRS/sepsis and shock.

NCT ID: NCT00736723 Completed - Sepsis Clinical Trials

NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock

NICUPS
Start date: August 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine the course of NT-proBNP plasma concentrations in the context of confounding parameters in postoperative/posttraumatic critically ill patients with severe SIRS/sepsis and shock.

NCT ID: NCT00628381 Not yet recruiting - Sepsis Clinical Trials

L-citrulline Supplementation During Sepsis

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the stimulating effects of prolonged (8h) enteral L-citrulline supplementation on the normalisation of the plasma citrulline concentrations and the Arginine-NO metabolism, the microcirculation, the systemic hemodynamics, vascular permeability, and organ function and disease severity scores.

NCT ID: NCT00483912 Suspended - Pancreatitis Clinical Trials

Albumindialysis in Acute Pancreatitis

pancreatitis
Start date: n/a
Phase: N/A
Study type: Interventional

The incidence of acute pancreatitis has been doubled during last three decades in Finland. Alcohol is the main cause of acute pancreatitis in Finland accounting for 70 % of cases. Although the mortality of acute pancreatitis has been decreased it still appears and especially early multiple organ failure is the main cause of all deaths. Multiple organ failure in the early course of the disease is thought to be caused by the release of cytokines. Molecular adsorbent recirculating system (MARS) has shown to decrease mortality in acute alcohol hepatitis and paracetamol intoxication. Also it has been shown to improve kidney function due to hypoperfusion and tubulus necrosis and overrule decrease mortality in patients with multiple organ failure due to different reasons. A part of patients with acute alcoholic pancreatitis may have so-called fat liver already on admission. It has been shown that the highest mortality is especially associated those with early liver and kidney failure. MARS treatment has never earlier been used in the patients with acute alcoholic pancreatitis and early organ failure. In this study we randomize patients with acute alcoholic pancreatitis and early multiple organ failure (Sofa score>2) to two groups: 1) Standard pancreatitis treatment in intensive care unit and 2) Standard pancreatitis treatment in intensive care unit with 5 MARS sessions.